Form 4: Nuvation Bio Inc. Executive Wang Junyuan Jerry Reports Acquisition and Conversion of Securities Following Merger

Wang Junyuan Jerry, CEO of AnHeart Therapeutics Ltd. and a director of Nuvation Bio Inc., reports the acquisition and conversion of Series A Preferred Stock and warrants into Class A Common Stock following the satisfaction of a convertibility condition related to the merger with AnHeart.

Summary

• On September 4, 2024, Wang Junyuan Jerry, a director and officer of Nuvation Bio Inc., reported transactions involving the company's securities.
• These transactions stem from the merger between Nuvation Bio Inc. and AnHeart Therapeutics Ltd.
• Mr. Wang acquired 2,543,600 shares of Class A Common Stock directly and 1,695,700 shares indirectly through WangWang, LLC.
• These acquisitions resulted from the conversion of Series A Preferred Stock into Class A Common Stock at a ratio of 100 shares of Class A Common Stock for each share of Series A Preferred Stock.
• The conversion was triggered by the satisfaction of a convertibility condition on September 3, 2024, which involved stockholder approval of the issuance of Class A common stock upon conversion of the Series A Preferred Stock and exercise of warrants.
• Mr. Wang also acquired warrants to purchase 86,471 shares of Class A Common Stock directly and 57,647 shares indirectly through WangWang, LLC, exercisable at $11.50, expiring on April 9, 2029.
• Following these transactions, Mr. Wang directly owns 3,922,589 shares of Class A Common Stock and indirectly owns 2,246,458 shares through WangWang, LLC.
• He also directly owns 86,471 warrants and indirectly owns 57,647 warrants through WangWang, LLC.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document primarily reports transactions related to a previously announced merger. The conversion of preferred stock to common stock is generally a positive simplification of the capital structure.

Positives

• The conversion of preferred stock to common stock simplifies the capital structure of Nuvation Bio Inc.
• The satisfaction of the convertibility condition removes a previous restriction on the securities.
• The increased holdings of Class A Common Stock by a director and officer could signal confidence in the company's future.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the US, ensuring transparency of insider transactions.
• The reporting requirements are governed by Section 16(a) of the Securities Exchange Act of 1934.
• Similar filings are made by executives and directors of comparable companies like Pfizer, Amgen, and Johnson & Johnson when they trade their company's stock.

Stakeholder Impact

• Shareholders may view the increased holdings of Class A Common Stock by a director and officer as a positive signal.
• The conversion of preferred stock to common stock could impact the overall shareholder equity structure.

Key Dates